Featured Research

from universities, journals, and other organizations

Pregnant women with high celiac disease antibodies are at risk for low birth weight babies

Date:
April 29, 2013
Source:
American Gastroenterological Association
Summary:
Pregnant women with mid to high levels of antibodies common in patients with celiac disease are at risk for having babies with reduced fetal weight and birth weight, according to a new study. The antibody tissue transglutaminase is most commonly found in patients with celiac disease.

Pregnant women with mid to high levels of antibodies common in patients with celiac disease are at risk for having babies with reduced fetal weight and birth weight, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. The antibody tissue transglutaminase (anti-tTG) is most commonly found in patients with celiac disease.

"While several observational studies have suggested that celiac disease is associated with different pregnancy outcomes, this research takes into account the actual levels of tissue transglutaminase that reflect the degree of mucosal damage associated with undiagnosed celiac disease or limited compliance to a gluten-free diet. This differentiation is critical since most celiac disease cases remain undiagnosed," said Jessica Kiefte-de Jong, MSc, Erasmus University Medical Center, and lead author of the study.

Researchers conducted a population-based perspective birth cohort study of 7,046 pregnant women, and categorized subjects into three groups: negative anti-tTG (control), intermediate anti-tTG (just below the clinical cut-off point used to diagnose patients with celiac disease) and positive anti-tTG (highly probable celiac disease patients). Fetuses of women with positive anti-tTG weighed 16 grams less than those of women with negative anti-tTG levels during the second trimester and weighed 74 grams less during the third trimester.

People with intermediate anti-tTG levels are generally not considered to be potential celiac disease patients, yet birth outcomes for these individuals were also affected. Infants of women with intermediate and positive anti-tTG weighted 53 grams and 159 grams less at birth, respectively, than those of women with negative anti-tTG.

"Researchers need to explore the natural history and long-term consequences of intermediate anti-tTG levels to determine if these levels are caused by pregnancy or whether it reflects a subclinical state of celiac disease that needs follow-up," added Jong.

Further helping to identify the connection between anti-tTG levels and celiac disease, a study in Clinical Gastroenterology and Hepatology reconfirms the recent European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines, which recognize that the likelihood for celiac disease increases with increasing antibody concentration.

Research from University Hospitals Leuven, Belgium, stresses the importance of also monitoring for relevant symptoms, such as weight loss, failure to thrive, anemia, iron deficiency or fatigue, when diagnosing patients, and notes that physicians should not rely solely on anti-tTG testing to make a diagnosis.

The study found that there is a 50 to 75 percent chance that persons without symptoms, but with anti-tTG levels more than 10 times the cutoff value, as defined in the ESPGHAN guidelines, will have celiac disease. The probability that a patient has celiac disease rises to 95 percent or higher when, in addition to high anti-tTG levels, the patient expresses complaints that can be associated with celiac disease.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Cite This Page:

American Gastroenterological Association. "Pregnant women with high celiac disease antibodies are at risk for low birth weight babies." ScienceDaily. ScienceDaily, 29 April 2013. <www.sciencedaily.com/releases/2013/04/130429164915.htm>.
American Gastroenterological Association. (2013, April 29). Pregnant women with high celiac disease antibodies are at risk for low birth weight babies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/04/130429164915.htm
American Gastroenterological Association. "Pregnant women with high celiac disease antibodies are at risk for low birth weight babies." ScienceDaily. www.sciencedaily.com/releases/2013/04/130429164915.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins